ZURZUVAE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZURZUVAE (ZURZUVAE).
Zurzuvae (zuranolone) is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in the central nervous system.
| Metabolism | Primarily metabolized by CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. |
| Excretion | Zuranolone is primarily eliminated via hepatic metabolism, with negligible renal excretion. Approximately 90% of a radiolabeled dose is recovered in feces (as metabolites), and less than 1% in urine as unchanged drug. |
| Half-life | The terminal elimination half-life is approximately 16–23 hours in healthy subjects, supporting once-daily dosing. The half-life may be prolonged in patients with hepatic impairment. |
| Protein binding | Zuranolone is highly protein bound (>99%), primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution is approximately 1.1–1.7 L/kg, suggesting extensive distribution into tissues, including the central nervous system. |
| Bioavailability | The absolute oral bioavailability is approximately 50%, due to first-pass metabolism. Food does not significantly affect bioavailability. |
| Onset of Action | Following oral administration, clinical effect (improvement in depressive symptoms) is observed as early as Day 3 of treatment, with peak plasma concentrations achieved around 1–2 hours post-dose. |
| Duration of Action | The therapeutic effect following a 14-day course of zuranolone persists beyond the dosing period, with symptom improvement maintained for up to several weeks post-treatment. The duration of action is supported by sustained plasma levels above therapeutically relevant thresholds. |
| Molecular Weight | 328.42 |
50 mg orally once daily at bedtime, with or without food, for 14 days.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended for severe renal impairment (eGFR <30 mL/min/1.73m²). |
| Liver impairment | Child-Pugh A (mild): no adjustment. Child-Pugh B (moderate): reduce dose to 25 mg once daily. Child-Pugh C (severe): not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). |
| Geriatric use | No specific dose adjustment recommended; clinical trials included patients ≥65 years, but experience limited. Monitor for adverse reactions. |
| 1st trimester | Insufficient human data; animal studies show developmental toxicity at high doses. Avoid unless benefit outweighs risk. |
| 2nd trimester | No adequate human studies; potential risk of fetal harm based on animal data. Use only if clearly needed. |
| 3rd trimester | May cause neonatal withdrawal syndrome if used near term; consider risk versus benefit. |
Clinical note
Comprehensive clinical and safety monograph for ZURZUVAE (ZURZUVAE).
| Placental transfer | Likely crosses placenta based on molecular weight and animal studies; exact degree unknown. |
| Breastfeeding | No human data on excretion in breast milk; animal studies indicate drug is excreted in milk. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during treatment. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to zuranolone or any excipientsConcomitant use with strong CYP3A4 inducers
| Precautions | Somnolence/sedation: May impair driving or operating machinery; avoid driving within 12 hours of administration., Suicidal thoughts and behaviors: Monitor for worsening depression or suicidality., Dosage adjustment required with moderate or strong CYP3A4 inhibitors. |
| Food/Dietary | Take Zurzuvae with a fatty meal (e.g., eggs, avocado, nuts) to increase absorption. Grapefruit and grapefruit juice may increase drug levels and should be avoided due to potential inhibition of CYP3A4. Avoid excessive intake of high-fat meals if monitoring weight gain, but ensure the medication is taken with fat. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: theoretical risk, no observed increase in malformations. Second/third trimester: no adverse fetal effects reported. |
| Fetal Monitoring | Monitor maternal mood, suicidality, and sedation. Fetal monitoring not routinely required; assess if maternal toxicity occurs. |
| Fertility Effects | No human data; animal studies show no impairment of fertility at therapeutic doses. |
| Clinical Pearls | Zurzuvae (zuranolone) is a neuroactive steroid GABA-A receptor positive allosteric modulator indicated for postpartum depression. Onset of action is rapid, often within 3 days. Monitor for excessive sedation, somnolence, and dizziness, especially during dose escalation. Avoid driving or operating heavy machinery within 12 hours of administration. May cause suicidal thoughts or behavior; monitor closely. Contraindicated with strong CYP3A4 inducers or inhibitors. Dose adjustment needed with moderate CYP3A4 inhibitors. Hepatic or renal impairment may require dose adjustment. |
| Patient Advice | Take Zurzuvae exactly as prescribed, typically once daily in the evening with fatty food to enhance absorption. · Do not drive or engage in hazardous activities for at least 12 hours after taking the medication due to risk of drowsiness and dizziness. · Report any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior immediately. · Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression. · If you miss a dose, skip it and take the next dose at the regular time. Do not double up. · Store at room temperature away from moisture and heat. Keep out of reach of children. |